SEC Comment Letter 0000000000-24-002165 to Allarity Therapeutics, Inc. (ALLR)

Allarity Therapeutics, Inc.
Date: Feb. 27, 2024 · CIK: 0001860657 · Accession: 0000000000-24-002165

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-41160

Date

February 27, 2024

Author

Thomas Jensen

Form

UPLOAD

Company

Allarity Therapeutics, Inc.

Letter

United States securities and exchange commission logo February 27, 2024 Thomas Jensen Chief Executive Officer Allarity Therapeutics, Inc. 24 School Street, 2nd Floor Boston, MA 02108 Re:Allarity Therapeutics, Inc. Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A Filed February 23, 2024 File No. 001-41160 Dear Thomas Jensen: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William Haddad

Show Raw Text

United States securities and exchange commission logo
February 27, 2024
Thomas Jensen
Chief Executive Officer
Allarity Therapeutics, Inc.
24 School Street, 2nd Floor
Boston, MA 02108
Re:Allarity Therapeutics, Inc.
Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A
Filed February 23, 2024
File No. 001-41160
Dear Thomas Jensen:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       William Haddad

SecProbe.io